Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 19

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 19
---

Precision diagnostics and personalized
care is about focusing on what is required for a specific patient, what are their individual needs, how can we understand more about them
to be more precise when delivering care and identifying the right clinical pathway to move them through treatment. Renovaro Cube technology
will bring a high level of detail with multi-omic data, allowing individual genes and different possible cancers under suspicion to be
identified. Due to the structure of the data produced, Renovaro Cube can bring it into any format of user interface, documentation, or
database. We expect to provide the flexibility to respond to the different requirements for delivering data to the right person at the
right place at the right time. We will comply to user interface guidance and usability regulations (WC3C) to ensure that they meet the
correct standards to enable the data to be displayed, read and understood. Personalized care is what we all in the healthcare system are
striving for, we are one component that can make a huge difference.

Future Development

In driving towards future commercialization,
Renovaro Cube intends to undertake or continue the following activities to enable the development of its AI platform, bolster the credibility
of this platform and open up revenue opportunities:

<div align='center'>13</div>

| ● | Increase in-kind contribution projects with hospitals, research centers and pharmaceutical                                                         
 companies, focusing on rare disease, cancer diagnosis and other opportunities for clinical trials; it is expected that the investments             
 required for these activities will be leveraged by non-dilutive funding instruments to de-risk individual projects and product development routes, |

| ● | Work to develop long-term strategic partnerships with clinical organizations, research centers and pharmaceutical companies to advance existing research in multi-modal analysis and open potential revenue streams; |

| ● | Develop Renovaro Cube’s multi-modal, multi-omics platform architecture and first prototypes, with the goal of providing integrated multi-modal solutions that would be sold as a fully deployed and fully supported solution, subject to compliance with regulatory standards for hosting and support and for production of algorithms being deployed in a clinical environment; |

| ● | Build Renovaro Cube’s service and support models for its AI platform; |

| ● | Build or lease a “supercomputer” that will be utilized for processing genomic data, the training of algorithms and the development of Renovaro Cube’s solutions; |

| ● | Continue business development across key territories in the Europe, Middle East, and Africa (“EMEA”) region, starting in the United Kingdom, the